Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Two-horse race for TPO

Two-horse race for TPO The thrombopoietin picture became a bit clearer last week, as Amgen Inc. and partner Kirin licensed rights to Novo Nordisk's technology covering the platelet booster. That leaves AMGN and Genentech Inc. to square off in the race to get through clinical development, and potentially in a battle over patent rights.

Novo Nordisk and its ZymoGenetics subsidiary licensed to Kirin, AMGN and their Kirin-Amgen joint venture rights to market and sell TPO. Novo Nordisk will receive

Read the full 865 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE